Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4173711
Max Phase: Preclinical
Molecular Formula: C48H86N12O12
Molecular Weight: 1023.29
Molecule Type: Small molecule
Associated Items:
ID: ALA4173711
Max Phase: Preclinical
Molecular Formula: C48H86N12O12
Molecular Weight: 1023.29
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)C[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)C[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(C)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)C(N)=O
Standard InChI: InChI=1S/C48H86N12O12/c1-10-27(6)34(56-45(69)32(16-13-14-20-49)54-46(70)35-17-15-21-60(35)30(9)62)23-38(65)58-42(29(8)12-3)48(72)55-33(18-19-36(50)63)44(68)53-31(25-61)22-37(64)57-40(26(4)5)47(71)52-24-39(66)59-41(43(51)67)28(7)11-2/h26-29,31-35,40-42,61H,10-25,49H2,1-9H3,(H2,50,63)(H2,51,67)(H,52,71)(H,53,68)(H,54,70)(H,55,72)(H,56,69)(H,57,64)(H,58,65)(H,59,66)/t27-,28-,29-,31+,32-,33-,34+,35-,40-,41-,42-/m0/s1
Standard InChI Key: BJQPVQHWOWXNKD-NPYZOWCXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1023.29 | Molecular Weight (Monoisotopic): 1022.6488 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. de Lucio H, Gamo AM, Ruiz-Santaquiteria M, de Castro S, Sánchez-Murcia PA, Toro MA, Gutiérrez KJ, Gago F, Jiménez-Ruiz A, Camarasa MJ, Velázquez S.. (2017) Improved proteolytic stability and potent activity against Leishmania infantum trypanothione reductase of α/β-peptide foldamers conjugated to cell-penetrating peptides., 140 [PMID:29017116] [10.1016/j.ejmech.2017.09.032] |
Source(1):